Booking Holdings: Street Cuts Targets After Q3 Print

Booking Holdings has just reported Q3 earnings, and the immediate read from the Street is a uniform round of target-price reductions, though no one is walking away from the stock.

The analyst response this morning was striking in its consistency. Ten firms reported updated views within hours of the print, and every single one that moved a price target moved it lower. Morgan Stanley cut from $230 to $200 while keeping Overweight. Barclays trimmed from $210 to $170, also holding Overweight. RBC Capital went from $220 to $205 at Outperform. The cuts are broad: Wedbush, Evercore ISI, Susquehanna, Wells Fargo and Piper Sandler all marked down their numbers. The revised consensus target settles around $231, still well above the current price of $155.67, implying roughly 48% upside on paper. The ratings themselves are holding, most of the desk is at Outperform or equivalent, but the target compression signals the Street is recalibrating its near-term growth assumptions, particularly around Q4 room-night guidance. The bear case that has been building through October, geopolitical disruption in France and the Middle East, weakening October reservation trends, and risk of Q4 room-night growth coming in at 2 to 4% rather than the 6% the Street had modelled, appears to have found enough supporting evidence in the print to push targets lower across the board.

Short positioning tells a more nuanced story. At 60.6% of the free float, the headline figure remains elevated. But that number has been moving in the right direction for BKNG longs: before Monday's small reversal, shorts had cut nearly 3 million shares over a single multi-day window in late October, pulling the SI% from above 22 million shares in mid-October to roughly 18.7 million. The ORTEX short score, at 32.8 on November 3, has actually drifted lower from the mid-34s seen on October 21 to 22, reflecting less aggressive short positioning rather than more. The borrow market provides no squeeze narrative: availability remains effectively unconstrained, with roughly 745 million shares available against just 19.5 million currently short, and the cost to borrow a negligible 0.37%. The incremental short interest added this week, up 4.1% on the week to November 3, looks more like tactical hedging around the print than a structural re-rating of conviction.

Options pricing has shifted in a direction consistent with the post-earnings relief bid. The put/call ratio has dropped to 0.78, more than two standard deviations below its 20-day average of 0.83. That is the lowest PCR reading in at least a year, well beneath the 52-week high of 0.92, and it reflects call positioning running unusually heavy relative to puts. For a stock down more than 2% over the past month, that degree of bullish options skew is notable. It aligns with the short-covering dynamic visible in the SI data: the positioning picture around the print was defensive into it, and appears to be unwinding out of it.

The fundamental debate is not new, but the Q3 print has sharpened it. The bull case rests on durable structural advantages: an estimated $185 billion to $186 billion in gross bookings, roughly 1.2 billion room nights, EBITDA margins in the mid-to-high 30s, and approximately 90% free-cash-flow conversion. The company's own buyback data, sourced from SEC EDGAR XBRL filings, adds a pointed data point: buyback spend rose 166% in the second quarter versus a year earlier, with 22 million shares repurchased, up 214% year on year. That is a capital return story the board has been telling loudly. Against that, the bears point to transaction momentum slowing to low-single-digit growth in the first three weeks of October, France at roughly 10% of global listings and the Middle East at an estimated 7% of 2025 room nights, and AI disintermediation risk as a structural overhang on marketing spend. Retail attention has picked up sharply: a Wikipedia views signal from the Wikimedia Foundation registered a z-score of 2.3 as of October 22, the highest attention reading relative to the prior 90 days, suggesting the Q3 setup drew meaningful interest beyond the institutional base.

Capital Research and Management Company stands out in the institutional register. As of September 30, the firm held 31.9 million shares, a position that had grown by more than 8.2 million shares in the most recent reported period. That is by far the largest directional addition among the top holders. BlackRock and Vanguard hold the two largest stakes at 8.7% and 7.3% of shares respectively, with Vanguard's main fund reporting a negligible change. The pattern of insider activity since August provides little signal in either direction: all recent trades have been pre-arranged 10b5-1 plan sales by the CHRO and General Counsel, modest in size and mechanical in nature.

The next earnings event is not until February 18, 2027. What matters between now and then is whether the Q4 room-night guide, the number the Street has been debating all quarter, lands closer to the bears' 2 to 4% scenario or the bulls' 6%, and whether the European and Middle Eastern disruption narrative stabilises or deepens before the winter travel season firms up.